Lawrence Greiten, M.D., is an Assistant Professor in the Division of Congenital Cardiac Surgery at Arkansas Children’s Hospital (ACH) and the University of Arkansas for Medical Sciences (UAMS).
Dr. Greiten received his undergraduate degree from Kansas Wesleyan University and his medical degree from the University Of Arizona College Of Medicine. He completed both his General Surgery training and Cardiovascular and General Thoracic Surgery fellowship at the Mayo School of Graduate Medical Education, where he also earned a Masters in Biomedical Sciences, Clinical and Translational Science. He did an advanced Fellowship in Congenital Cardiac Surgery at Children’s Hospital Los Angeles, Keck Medical School at the University of Southern California.
A native of Milwaukee, Wisconsin, Dr. Greiten joined the team at ACH and UAMS in 2018. He is board certified by the American Board of Surgery and the American Board of Thoracic Surgery. Dr. Greiten is a member of the Society of Thoracic Surgeons, the American Heart Association, the American Association of Thoracic Surgery, and both the Southern and Eastern Cardiothoracic Surgery Societies. His clinical interests include congenital malformations and surgical treatment, as well as thromboprophylaxis and quality improvement of post-operative care. His research interests include neurodevelopmental outcomes in children with congenital heart defects, including hypoplastic heart syndrome, Tetralogy of Fallot, and Trisomy 21; in addition to minimally invasive surgical techniques and surgical innovation.
Dr. Greiten is double board certified in Surgery and Thoracic Surgery, with advanced formal training in Congenital Cardiac Surgery. He currently holds the position of Assistant Professor through the University of Arkansas for Medical Sciences (UAMS), serving as a congenital heart surgeon at Arkansas Children’s Hospital. His practice includes neonatal, pediatric and adult patients with congenital heart diseases.
Dr. Greiten has a Master’s in Biomedical, Clinical and Translational Science. While obtaining his master’s, he completed two years dedicated to basic science research utilizing both small and large animal models, cell line culture and analysis (FISH), and several analytical techniques in molecular biology and immunogenetics to determine specific proteins and RNA from tissue homogenate/extracts. Dr. Greiten has presented both nationally and internationally and was recognized as a world’s expert in the use of novel anticoagulants for thromboembolic protection in patients with mechanical heart valves. Since completing fellowship training, the majority of his research work has been on neonatal and pediatric patients with congenital heart diseases, specifically children with single ventricle physiology who undergo either palliation (Norwood/Hybrid, Glenn, Fontan) or pediatric heart transplantation.
Areas of research for which Dr. Greiten has a particular interest include clinical outcomes of palliative and definitive repairs of congenital cardiovascular malformations; neurodevelopmental outcomes after cardiac surgery; hypoplastic heart, palliative repair and transplantation; thromboprophylaxis of mechanical and bioprosthetic heart valves; minimally invasive cardiac and endovascular techniques; post-surgical pediatric cardiac critical care outcomes; and role of gender and hormone status on cardiac hypertrophy and myocardial remodeling.
All patient satisfaction surveys are submitted by verified patients and families of Arkansas Children's. The star rating is an average of all responses to the provider-related questions by an independent patient satisfaction company. Responses are measured on a scale of 1 to 5 with 5 being the best score. The comments listed reflect the positive experiences submitted by patients and families through the survey process. The comments are not endorsed by and do not necessarily reflect the views or Arkansas Children's.
Every day at Arkansas Children’s Heart Institute, we strive for excellence, and our outcomes prove it. Under the direction of nationally renowned pediatric cardiothoracic surgeon Dr. Brian Reemtsen, the Heart Institute achieved a remarkable 100% surgical survival rate last year, including transplants.